Allinaire Therapeutics, LLC

CLEVELAND, OH · Founded 2015 · CIK 0001676987 · Biotech · Private

Humanized monoclonal antibody (mAb) targeting EMAP II for emphysematous COPD treatment

allinaire.com →
Grants
$3.0M
4 awards
Sector median: 1
Raised
$950K
1 Form D · Dec 2016
118 months since last filing
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$950,000
Federal grantDepartment of Health and Human Services · Phase I · Development of a Fully Humanized Antibody for Treating Lung Emphysema$52,013
Federal grantDepartment of Health and Human Services · Phase II · Development of a Fully Humanized Antibody for Treating Lung Emphysema$1,673,916
Federal grantDepartment of Health and Human Services · Phase I · Humanized EMAP II mAb as a Novel Therapy for Viral-Associated Lung Injury$281,155
Federal grantDepartment of Health and Human Services · Phase II · Development of a Fully Humanized Antibody for Treating Lung Emphysema$958,776
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2358NEW EQUILIBRIUM BIOSCIENCES, INC.—$10M
2359Metalytics, LLC——
2360OLIGOMERIX INC—$2.9M
2361Allinaire Therapeutics, LLC—$950K
2362ECM Therapeutics, Inc.—$919K
2363ACRIGEN BIOSCIENCES, INC.—$775K
2364MARCH BIOSCIENCES INC—$22M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Baiju ShahDirector · Executive Officer
  • Brian StemmeDirector
  • Ted TorphyDirector

Patents

USPTO · 0 granted of 3
  • Humanized Anti-emap II Therapeutic Antibodiesapplication
  • Humanized Anti-emap II Therapeutic Antibodiesapplication
  • Humanized Anti-EMAP II Therapeutic Antibodiesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.